News >

Hydrocortisone Reduces Hypersensitivity Reactions in Women With Gynecologic Cancers

Jason Harris
Published: Friday, Oct 13, 2017

Adding IV hydrocortisone (HCT) to standard dexamethasone (DXM) prophylaxis reduced the incidence of hypersensitivity reactions (HSR) in women undergoing paclitaxel-based treatment for gynecologic cancers.

Patients discontinued treatment if they manifested paclitaxel HSRs of grade ≥3 or stopped receiving paclitaxel because of intentional change of chemotherapy regimen for clinical reasons such as tumor nonresponse.
Jeerakornpassawat D, Suprasert P. Randomized, controlled trial of dexamethasone versus dexamethasone plus hydrocortisone as prophylaxis for hypersensitivity reactions due to paclitaxel treatment for gynecologic cancer. Int J Gynecol Cancer. Int J Gynecol Cancer. 2017;27(8):1794-1801 doi: 10.1097/IGC.0000000000001069.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication